Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

Accounting Policies [Abstract]

Schedule of financial assets and liabilities measured and recognized at fair value

Financial assets and liabilities measured and recognized at fair value are as follows:

	June 30, 2023
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	11,281	$	11,281	$	—	$	—
Investment in Syros Pharmaceuticals, Inc. ("Syros")	1,380		1,380		—		—
Investment in Enalare Therapeutics, Inc.	16,952		—		—		16,952
Acquisition rights of Enalare Therapeutics, Inc.	8,125		—		—		8,125

	December 31, 2022
	Total		Level 1		Level 2		Level 3
Assets:
Money market funds	$	47,567	$	47,567	$	—	$	—
Investment in Syros Pharmaceuticals, Inc. ("Syros")	1,573		1,573		—		—
Investment in Enalare Therapeutics, Inc.	8,438		—		—		8,438
Acquisition rights of Enalare Therapeutics, Inc.	8,125		—		—		8,125
Liabilities:
Forward Liability	$	4,063	$	—	$	—	$	4,063

Schedule of revenues and accounts receivables by major customers

The total revenues and accounts receivables broken down by major customers as a percentage of the total are as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Total revenues
Teva - See Revenue Recognition	38	%	36	%	35	%	29	%
Customer A	35	%	19	%	33	%	19	%
Customer B	10	%	7	%	12	%	12	%
Customer C	5	%	12	%	7	%	13	%
Customer D	8	%	7	%	8	%	9	%
Other	4	%	19	%	5	%	18	%
	100	%	100	%	100	%	100	%

	June 30,		December 31,
	2023		2022
Accounts receivable
Teva - See Revenue Recognition	19	%	31	%
Customer A	61	%	1	%
Customer B	13	%	57	%
Customer C	1	%	5	%
Customer D	6	%	2	%
Other	0	%	4	%
	100	%	100	%

Schedule of dilutive and anti-dilutive common shares equivalents outstanding

The anti-dilutive common share equivalents outstanding for the three and six months ended June 30, 2023 and 2022 were as follows:

	Three Months Ended June 30,		Six Months Ended June 30,
	2023	2022	2023	2022
Stock options	2,351,791	2,499,165	2,351,791	2,092,420
Restricted stock units	400,917	77,149	251,867	77,149
Total	2,752,708	2,576,314	2,603,658	2,169,569

Computation for basic and diluted net (loss) earnings per share

The following table sets forth the computation for basic and diluted net earnings (loss) per share for the three and six months ended June 30, 2023 and 2022:

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
Numerator
Net income (loss)	$	5,164	$	(9,450)	$	10,914	$	34,608
Denominator
Basic weighted average common shares outstanding	13,090,852		12,836,116		13,075,090		12,773,727
Dilutive effect of stock awards	63,747		—		76,017		178,061
Diluted weighted average common shares outstanding	13,154,599		12,836,116		13,151,107		12,951,788
Basic net earnings (loss) per share
Basic net earnings (loss) per share	$	0.39	$	(0.74)	$	0.83	$	2.71
Diluted net earnings (loss) per share
Diluted net earnings (loss) per share	$	0.39	$	(0.74)	$	0.83	$	2.67